

Datasheet: MCA1777S

Description:	MOUSE ANTI DOG CD11b	
Specificity:	CD11b	
Other names:	INTEGRIN ALPHA M CHAIN, MAC-1	
Format:	S/N	
Product Type:	Monoclonal Antibody	
Clone:	CA16.3E10	
lsotype:	lgG1	
Quantity:	2 ml	

Product Details

 Applications
 This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.biorad-antibodies.com/protocols.

		Yes	No	Not Determined	Suggested Dilution	
	Flow Cytometry	-			Neat	
	Immunohistology - Frozen	-				
	(1)					
	Immunohistology - Paraffin					
	ELISA					
	Immunoprecipitation	•				
	Western Blotting					
	Where this product has not been tested for use in a particular technic		nnique this does not			
	necessarily exclude its use in such procedures. Suggested working diluti				g dilutions are given as	
	a guide only. It is recomn	nended th	at the us	er titrates the product f	or use in their own	
	system using appropriate negative/positive controls.					
		ised by this antibody is reported to be sensitive to				
	formaldehyde fixation and tissue processing. Bio-Rad recommends the use of					
	acetone fixation for frozen sections.					
Target Species	Dog					
Species Cross	Reacts with: Goat, Cat, Mustelid, Pig, Bovine, Mink, Beluga whale N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.					
Reactivity						

Product Form	Tissue culture supernatant - liquid
Preservative Stabilisers	<0.1% sodium azide (NaN ₃)
Immunogen	Affinity purified beta-2 integrins from splenic lysate
RRID	AB_322922
Specificity	Mouse anti Dog CD11b antibody, clone CA16.3E10 is a monoclonal antibody recognizing the canine CD11b cell surface antigen, a member of the alpha integrin family. CD11b forms one of the possible alpha chains of the canine leukocyte adhesion complexes (LeuCAMs), these contain a common 95 kDa β chain (CD18) non-covalently bound to either a 150 kDa (CD11c), 165 kDa (CD11b) or 180 kDa (CD11a) α chain (Moore <i>et al.</i> 1990. The CD11/CD18 complex is also known as the CR3 receptor.
Flow Cytometry	Use 10µl of the suggested working dilution to label 10^6 cells or $100µl$ whole blood
References	 Danilenko, D.M. <i>et al.</i> (1992) Canine leukocyte cell adhesion molecules (LeuCAMs): characterization of the CD11/CD18 family. <u>Tissue Antigens 40: 13-21.</u> Brodersen, R. <i>et al.</i> (1998) Analysis of the immunological cross reactivities of 213 well characterized monoclonal antibodies with specificities against various leucocyte surface antigens of human and 11 animal species. <u>Vet Immunol Immunopathol. 64 (1): 1-13.</u> Kruger, E.F. <i>et al.</i> (2003) Bovine monocytes induce immunoglobulin production in peripheral blood B lymphocytes. <u>Dev Comp Immunol. 27 (10): 889-97.</u> Kamstock, D. <i>et al.</i> (2006) Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. <u>Cancer Gene Ther. 13: 306-17.</u> Sampaio, W.M. (2007) <i>In vitro</i> binding and survival assays of <i>Leishmania</i> parasites to peripherical blood monocytes and monocyte-derived macrophages isolated from dogs naturally and experimentally infected with <i>Leishmania chagasi.</i> <u>BMC Vet Res. 3:11.</u> Yuasa, K. <i>et al.</i> (2009) Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. <u>Mol Ther. 17: 1427-33.</u> Maiolini, A. <i>et al.</i> (2012) Toll-like receptors 4 and 9 are responsible for the maintenance of the inflammatory reaction in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. <u>J Neuroinflammation. 9: 226.</u> Sherger, M. <i>et al.</i> (2012) Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. <u>BMC Vet Res. 8: 209.</u>

10. Wasserman, J. *et al.* (2012) Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells. <u>Vet Immunol Immunopathol. 145 (1-2): 420-30.</u>

11. Paltrinieri, S. *et al.* (2012) Flow cytometric detection of alpha-1-acid glycoprotein on feline circulating leucocytes. <u>Aust Vet J. 90 (8): 291-6.</u>

12. Yu, D.H. *et al.* (2012) Pathophysiologic and immunologic changes in a canine endotoxemia over a period of 24 hours. <u>J Vet Med Sci. 74 (5): 537-44.</u>

13. Mastrorilli, C. *et al.* (2012) Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping. <u>Vet Clin Pathol. 41 (3): 412-8.</u>

14. Vermeulen, B.L. *et al.* (2013) Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. <u>Vet Microbiol. 164 (1-2):</u> <u>46-59.</u>

Figueiredo, M.M. *et al.* (2013) Expression of Toll-like Receptors 2 and 9 in cells of dog jejunum and colon naturally infected with *Leishmania infantum*. <u>BMC Immunol. 14: 22.</u>
 Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. <u>Vet Immunol Immunopathol. 155 (3): 211-7.</u>

17. Olyslaegers, D.A. *et al.* (2013) Altered expression of adhesion molecules on peripheral blood leukocytes in feline infectious peritonitis. <u>Vet Microbiol. 166 (3-4): 438-49.</u>

18. Guth, A.M. *et al.* (2013) Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. <u>Vet Comp Oncol. 11 (4): 296-305.</u>

19. Wijewardana, V. *et al.* (2013) Production of canine soluble CD40 ligand to induce maturation of monocyte derived dendritic cells for cancer immunotherapy. <u>Vet Immunol Immunopathol. 156 (1-2): 121-7.</u>

20. Thompson, L.A. & Romano, T.A. (2015) Beluga (*Delphinapterus leucas*) granulocytes and monocytes display variable responses to *in vitro*. pressure exposures. <u>Front Physiol.</u> <u>6: 128.</u>

21. Gow, A.G. *et al.* (2016) Low-Density Lipoprotein Uptake Demonstrates a Hepatocyte Phenotype in the Dog, but Is Nonspecific. <u>Stem Cells Dev. 25 (1): 90-100.</u>

22. Kuraoka, M. *et al.* (2016) Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. <u>Am J Pathol. 186 (5): 1302-12.</u>

23. Wang, L. *et al.* (2019) Electroacupuncture-induced cannabinoid receptor expression in repair of abducens nerve. <u>Int J Neurosci. 129 (9): 923-9.</u>

24. Hutchison, S. *et al.* (2019) Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy. <u>Vet Immunol Immunopathol. 216: 109912.</u>

25. Beirão, B.C.B. *et al.* (2020) A blocking antibody against canine CSF-1R maturated by limited CDR mutagenesis <u>Antibody Ther: 3.3: 193–204.</u>

26. Thompson, L.A. & Romano, T.A. (2019) Effects of health status on pressure-induced changes in phocid immune function and implications for dive ability. <u>J Comp Physiol B.</u> <u>189 (5): 637-57.</u>

27. Jarosz, Ł. *et al.* (2022) The Effect of Feed Supplementation with EM Bokashi® Multimicrobial Probiotic Preparation on Selected Parameters of Sow Colostrum and Milk as Indicators of the Specific and Nonspecific Immune Response. <u>Probiotics Antimicrob</u> <u>Proteins. 14 (6): 1029-1041.</u>

28. Knebel, A. *et al.* (2021) Measurement of canine Th17 cells by flow cytometry. <u>Vet</u> <u>Immunol Immunopathol. 243: 110366.</u>

29. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4targeted immunity in dogs with oral melanoma: a veterinary trial. <u>J Immunother Cancer.</u>

	<u>10(5):e004007.</u>				
	30. Troupel, T. et al. (2022) Generalised idiopathic polymyositis mimicking masticatory				
	myositis in a dog <u>Veterinary Record Case Reports. 2022;10:e452</u> 31. Wesolowski, M. <i>et al.</i> (2023) Long-term changes of Th17 and regulatory T cells in peripheral blood of dogs with spinal cord injury after intervertebral disc herniation. <u>BMC</u>				
	<u>Vet Res. 19 (1): 90.</u> 32. Bencze, M. <i>et al.</i> (2023) Receptor interacting protein kinase-3 mediates both myopathy and cardiomyopathy in preclinical animal models of Duchenne muscular				
	dystrophy. J Cachexia Sarcopenia Muscle. Nov 01 [Epub ahead of print].				
	33. Mason, N.J. et al. (2021) Development of a fully canine anti-canine CTLA4				
	monoclonal antibody for comparative translational research in	dogs with spontaneous			
	tumors. <u>MAbs. 13 (1): 2004638.</u>				
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.				
	Avoid repeated freezing and thawing as this may denature the frost-free freezers is not recommended.	antibody. Storage in			
Guarantee	12 months from date of despatch				
Health And Safety Information	Material Safety Datasheet documentation #10053 available at: https://www.bio-rad-antibodies.com/SDS/MCA1777S 10053				
Regulatory	For research purposes only				

Related Products

Recommended Secondary Antibodies

Rabbit Anti Mouse IgG (STAR12)	RPE			
Goat Anti Mouse IgG IgA IgM (STAR87) <u>HRP</u>				
Goat Anti Mouse IgG (STAR76)	RPE			
Goat Anti Mouse IgG (STAR70)	<u>FITC</u>			
Rabbit Anti Mouse IgG (STAR13)	HRP			
Goat Anti Mouse IgG (Fc) (STAR120)	FITC, HRP			
Rabbit Anti Mouse IgG (STAR9)	<u>FITC</u>			
Goat Anti Mouse IgG (STAR77)	HRP			
Goat Anti Mouse IgG (H/L) (STAR117)	Alk. Phos., DyLight®488, DyLight®550,			
	DyLight®650, DyLight®680, DyLight®800,			
	<u>FITC</u> , <u>HRP</u>			

Recommended Negative Controls

MOUSE IgG1 NEGATIVE CONTROL (MCA928)

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

 North & South
 Tel: +1 800 265 7376

 America
 Fax: +1 919 878 3751

Worldwide

Tel: +44 (0)1865 852 700 **Europe** Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com

'M437193:250310'

Printed on 10 Mar 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint